ArticleJournal of translational medicine2026
ProptoView: AI-based digital exophthalmometry using multi-view facial images in a multinational validation study.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundAccurate proptosis measurement is vital for managing thyroid eye disease (TED) and other orbital conditions. However, current approaches have certain limitations: the Hertel exophthalmometer is convenient but imprecise, while computed tomography (CT) is accurate but costly and exposes patients to radiation.
methodsWe developed ProptoView, an AI-based digital exophthalmometer, using 5676 images from 2516 eyes across 1258 visits of 763 TED patients with CT and Hertel measurements. For external validation, we used an additional 644 images from 648 eyes of 324 patients with TED and other orbital diseases, collected across three countries and five hospitals. Patients provided up to five images from four views. A three-stage deep learning approach, optimized with Adam and validated via five-fold cross-validation, helped develop three AI models: single-view, multi-view, and dynamic input.
resultsCompared with CT, the single-view model achieved an intraclass correlation coefficient (ICC) of 0.859, slightly lower than the Hertel exophthalmometer's ICC of 0.888. The multi-view model achieved an ICC of 0.890, surpassing the Hertel exophthalmometer (0.871). The dynamic input model achieved the highest accuracy with an ICC of 0.901. Among two-view combinations, pairing the frontal view with another angle showed the highest agreement when paired with the upward gaze view (ICC = 0.855). In external validation, ProptoView showed robust concordance with the Hertel exophthalmometer (ICC = 0.845), comparable to its agreement in the development dataset. Additionally, ProptoView reduced misclassification at the 19-mm threshold (14.7% vs. 20.5% with the Hertel exophthalmometer).
conclusionProptoView provides an accurate, non-contact, and cost-effective solution for proptosis measurement. Its flexibility and precision suggest significant potential for streamlining clinical workflows and enabling telemedicine applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.